Radiopharm Completes RAD 101 Phase 2b Enrollment; 90% MRI Concordance

Radiopharm Theranostics completed enrollment in its Phase 2b clinical trial for imaging agent RAD 101, which demonstrated 90% concordance with MRI in patients with recurrent brain metastases. The company also presented initial Phase 0/1 data for RAD 202, showing encouraging tumor uptake and a favorable safety profile, leading to a positive recommendation from the DSMC to advance to the next dose level. Furthermore, Radiopharm initiated two new First-In-Human clinical trials for radiotherapeutic assets RV-01 and RAD 402, expanding its therapeutic pipeline.